Ionis Pharmaceuticals (IONS) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 109.3% versus a loss of 38.1%. Over five years, KNSA leads with a +587.8% price change compared with +23.4% for IONS. Ionis Pharmaceuticals is the larger company by market cap ($7.52 billion vs $6.22 billion), about 1.2 times the size, while Kiniksa Pharmaceuticals International is growing revenue faster (+60.1% vs +33.8%).
Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus -40.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IONS | KNSA |
|---|---|---|
| Share price | $45.28 | $79.78 |
| Market cap | $7.52B | $6.22B |
| 1-day change | +4.57% | +1.31% |
| YTD return | -45.27% | +93.41% |
| 1-year return | -38.11% | +109.34% |
| 5-year return | +23.36% | +587.77% |
| P/E ratio (TTM) | — | 79.78 |
| Forward P/E | — | 49.32 |
| EPS (TTM) | $-3.48 | $1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $943.71M | $677.56M |
| Revenue growth (YoY) | +33.83% | +60.09% |
| Net income (latest FY) | $-381.39M | $59.01M |
| Gross margin | 98.31% | 88.54% |
| Operating margin | -40.45% | 11.40% |
| Net margin | -40.41% | 8.71% |
| 52-week high | $86.74 | $82.94 |
| 52-week low | $42.63 | $35.20 |
| Distance from 52-week high | -47.80% | -3.81% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +84.72% | +22.84% |
| Average volume | 3.51M | 573.74K |
| Shares outstanding | 166.18M | 48.29M |
| Employees | 1,480 | 366 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KNSA has outperformed IONS by 147.4 percentage points over the past year.
- Kiniksa Pharmaceuticals International is more profitable, keeping 8.7 cents of every revenue dollar as net income versus -40.4 cents for Ionis Pharmaceuticals.
- Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs +33.83%).
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,480 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
IONS vs KNSA FAQ
Which is bigger, Ionis Pharmaceuticals or Kiniksa Pharmaceuticals International?
Ionis Pharmaceuticals (IONS) is larger, with a market capitalization of $7.52B compared with $6.22B for Kiniksa Pharmaceuticals International (KNSA).
Which stock has performed better over the past year, IONS or KNSA?
KNSA returned +109.34% over the past 12 months, compared with -38.11% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Ionis Pharmaceuticals and Kiniksa Pharmaceuticals International in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.